... that there has not been more dot-connecting by institutions and larger investors between Healios and ATHX thus far to move this stock higher. Volume in ATHX has been lower than average for a large number of recent trading sessions, despite the fact that the Japan strategy and Healios investment is public knowledge.
A few thoughts here:
1. We're assuming on this board that Healios' movement is due to ATHX. Might it not be?
2. ATHX still is a micro-cap and is flying below many institutions' radar.
3. Once burned, twice burned, many-times burned investors in bio/stem cell are still wary?
One would have thought the Stanford results would have sent some strapping young research analysts digging in the NASDAQ trenches, but not yet...